Europäische Union - Litauisch - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresantai - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Europäische Union - Litauisch - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologai - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europäische Union - Litauisch - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologai - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europäische Union - Litauisch - EMA (European Medicines Agency)

sandoz gmbh - trastuzumabas - breast neoplasms; stomach neoplasms - antinavikiniai vaistai - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).

Europäische Union - Litauisch - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologai - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Litauen - Litauisch - SMCA (Valstybinė vaistų kontrolės tarnyba)

as grindeks - oksitocinas - injekcinis ar infuzinis tirpalas - 5 tv/ml - oxytocin

Litauen - Litauisch - SMCA (Valstybinė vaistų kontrolės tarnyba)

as grindeks - oksitocinas - injekcinis ar infuzinis tirpalas - 10 tv/ml - oxytocin

Litauen - Litauisch - SMCA (Valstybinė vaistų kontrolės tarnyba)

accord healthcare b.v. - bupivakainas - injekcinis tirpalas - 2,5 mg/ml; 5 mg/ml - bupivacaine

Litauen - Litauisch - SMCA (Valstybinė vaistų kontrolės tarnyba)

as grindeks - ipidakrino hidrochloridas - injekcinis tirpalas - 5 mg/ml - anticholinesterases

Litauen - Litauisch - SMCA (Valstybinė vaistų kontrolės tarnyba)

as grindeks - ipidakrino hidrochloridas - injekcinis tirpalas - 15 mg/ml - anticholinesterases